Epigenomics AG Overview
Pro stress-test →Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using DNA methylation technology. The company focuses on liquid biopsy for the early detection of cancer, with its lead product Epi proColon, a blood-based test for early detection of colorectal cancer in the United States, Europe, and China.
Strategic Profile
Pro stress-test →The company leverages proprietary DNA methylation technology to develop non-invasive blood tests for cancer screening and monitoring across multiple cancer indications. Epigenomics competes in the emerging liquid biopsy market, positioning itself as a developer of diagnostic tests that enable earlier cancer detection through accessible blood sampling rather than more invasive procedures.
Competitive Landscape
Pro stress-test →Epigenomics competes in the liquid biopsy and molecular diagnostics space against established diagnostics companies and specialized biotech firms developing blood-based cancer tests. Key competitors include companies offering alternative detection technologies (ctDNA-based assays, protein biomarkers) and larger diagnostics platforms integrating multiple cancer detection methods.
Industry Context
Epigenomics AG operates in Liquid biopsy and blood-based cancer diagnostics.
Key facts
Founded: 2002 · Headquarters: Berlin, Germany · Employees: N/A · Revenue: N/A · Market cap: N/A